GeneDx

GeneDx was founded in 2000 by scientists Sherri Bale and John Compton from the National Institutes of Health (NIH). The company was established to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which limited commercial testing options existed at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, GeneDx was acquired by BioReference Laboratories and continued to operate as a subsidiary. In October 2016, Benjamin D. Solomon was appointed as managing director. In 2021, Katherine Stueland became CEO of GeneDx. GeneDx was acquired by Sema4 in 2022, and Stueland was named CEO of the combined company. In 2023, the combined company underwent a strategic transformation, refocusing on whole exome and genome sequencing in pediatrics, and changed its name to GeneDx. The recognition highlighted the company's work in advancing genomic sequencing and data-driven approaches to improve rare disease diagnosis. GeneDx settled a patent dispute with Myriad Genetics in February 2015 after GeneDx launched a BRCA mutation breast cancer genetic screening test following the US Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. that concluded isolated gene sequences were patent ineligible. == Management ==

Katherine Stueland was appointed CEO of GeneDx in 2021. and to the TIME100 Health list in 2026. Kevin Feeley was appointed CFO in 2022. Prior to joining GeneDx, Feeley served as CFO of BioReference Laboratories and held senior roles at KPMG LLP. Bryan Dechairo was appointed COO in 2025. == Products and Services ==

GeneDx offers genetic testing services with a primary focus on whole genome sequencing (WGS) and whole exome sequencing (WES). WGS provides a comprehensive analysis of an individual's entire genome, while WES focuses on protein-coding regions called exons, which contain a majority of known disease-related genetic variants. The company's tests are used in clinical diagnostics, research, and precision medicine by geneticists, genetic counselors, neonatologists, pediatric specialists, and pediatricians. GeneDx offers testing for conditions including rare diseases, autism spectrum disorders, epilepsy, neurodevelopmental disorders, cardiomyopathies, and inherited conditions affecting vision, the immune system, muscles, hearing, metabolism, neurology, and mitochondrial diseases. GeneDx also offers rapid sequencing options intended for critically ill pediatric and neonatal patients where timely results may influence acute medical management. GeneDx continues to develop genetic testing technologies and expand access to genomic information for clinical use in pediatric, adult, and newborn populations. Professional guidelines from organizations such as the American College of Medical Genetics and Genomics (ACMG) and the American Academy of Pediatrics (AAP) support the use of exome or genome sequencing as first-line or early diagnostic tests in selected patient populations. GeneDx's biopharma business focuses on leveraging GeneDx Infinity to provide partners with access to molecularly confirmed genomic data, longitudinal patient information, and curated phenotypic data to support drug discovery, clinical development, real-world evidence generation and other therapeutic development needs. By combining large-scale sequencing data with clinical and phenotypic context, the company aims to accelerate rare disease research and improve the efficiency and success rate of biopharmaceutical development programs. == Developments and Milestones ==

Breakthrough Device Designation In October 2025, the company's ExomeDx and GenomeDx testing was granted FDA Breakthrough Device designation for use in diagnosing symptomatic patients with life-threatening diseases or genetic disorders. Acquisition of Fabric Genomics In April 2025, GeneDx announced the acquisition of Fabric Genomics, an AI-powered genomic interpretation company. The transaction closed in May 2025 for up to $33 million in cash at closing, with total consideration potentially reaching $51 million upon achievement of certain milestones. Financial Performance In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter in October 2024. Genomic Newborn Screening GeneDx is a sequencing and interpretation partner in the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, a research initiative examining whether whole genome sequencing can improve health outcomes for newborns. The study is conducted in collaboration with Columbia University, NewYork-Presbyterian, the New York State Department of Health, and Illumina. Results from the study were published in JAMA in October 2024, reporting a 3.7% screen-positive rate among enrolled newborns. 92% of true-positives would not have been detected using standard newborn screening technology. The study has enrolled over 20,000 newborns and expanded its panel to include 446 genes associated with more than 460 actionable conditions. == Research Contributions ==

GeneDx researchers have contributed to peer-reviewed publications in major scientific and medical journals, generating critical data to expand access to genomic testing. In 2020, GeneDx researchers co-authored a study published in Nature analyzing data from 31,058 exome trios to identify 28 previously undescribed genes associated with developmental disorders, providing diagnoses for approximately 500 families. A 2021 study in JAMA, using data from GeneDx, found that exome sequencing identified pathogenic or likely pathogenic variants in 32.7% of pediatric patients with cerebral palsy, providing evidence to support genetic testing guidelines for the condition. In 2025, GeneDx collaborated with Seattle Children's and the University of Washington on the SeqFirst research program, which produced two landmark publications. The SeqFirst-Neo study, published in the American Journal of Human Genetics, found that applying broad exclusion criteria for rapid genome sequencing in NICUs increased the odds of a precise genetic diagnosis ninefold compared to conventional care, with 42% of diagnosed infants having been missed under standard protocols. A companion study published in The Journal of Pediatrics demonstrated that implementing rapid genome sequencing as a first-tier test in non-critical pediatric inpatient wards reduced the average time to a precise genetic diagnosis from 289 days to 13 days. As of 2025, GeneDx has contributed to more than 1,100 peer-reviewed publications and contributes to more than 500 validated gene-disease associations through the GeneMatcher platform. In 2026, GeneDx researchers published a validation study in Human Genetics describing Multiscore, an AI-powered gene prioritization tool, that combines machine learning with real-world clinical data from the GeneDx database alongside published literature and OMIM, correctly prioritized the causative gene within the top 10 candidates in 83.5% of cases, outperforming existing phenotype-based prioritization tools including Phrank and LIRICAL. A 2026 real-world health economics analysis (SAVES-Kids), presented at the American College of Medical Genetics (ACMG) annual meeting, found GeneDx's exome and genome sequencing reduced total healthcare costs by up to 61% in the 12 months following testing for children with neurodevelopmental disorders. For children with epilepsy, that represents an average of approximately $80,000 per patient per year. == References ==